Gastrointestinal stromal tumour Program in Pharmaceutical Benefits Scheme (PBS) 012-18053000
Expand allThis document outlines details of PBS-subsidised imatinib, ripretinib and sunitinib for patients with gastrointestinal stromal tumour (GIST).
For details on how to process a PBS Authority, see Processing Complex Authority Required Listings.
Gastrointestinal stromal tumour (GIST) quick reference
| Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
| Initial Adjuvant or Metastatic/Unresectable | Telephone Electronic S85: | No | OPA | Not specified | Yes |
| Initial Metastatic/Unresectable form | Written Electronic S85: | No | OPA | Not specified | Yes |
| Initial Metastatic/Unresectable | Telephone Electronic S85: ripretinib | No | OPA | Not specified | Yes |
| Continuing Adjuvant or Metastatic/Unresectable | STREAMLINED S85: | No | OPA | Not specified | N/A |
| Continuing Metastatic/Unresectable | STREAMLINED S85: sunitinib | No | OPA | Not specified | N/A |
| Continuing Metastatic/Unresectable | Telephone Electronic S85: | No | OPA | Not specified | Yes |